Weekly
π£π The next evolution: MP1π; 4DX derisking EU; XEN turnaround on track; AVE the next big biotech?
HOMODEUS RESEARCH WEEKLY BRIEF Β· 6 June 2026 We got merch! Not really research related per se but my most exciting development this week was getting merch! π₯³ This week we also had a riveting discussion with Avecho (ASX:AVE) CEO Paul Gavin. You can watch the video here . Feeling generous? Iβve just signed up to the push-up challenge this year. With all my donations going to support headspace, Australiaβs National Youth Mental Health Foundation. You donate here . NEWS THIS WEEK 4DMedical Limited (ASX:4DX) targets US$2.5B PE market entry for CTVQ . Creates EU platform via contextflow acquisition. Source: Pulmonary Embolism | EU platform HD View: Strong set of announcements. We previously saw execution risk entering into EU given lack of footprint. Contextflow acquisition materially derisks 4DXβs entry into EU/UK. Xenitra Ltd (ASX:XEN) 1.) $1.1m in OPAL-Tokenised Product Sales in First 7 Weeks; 2.) Appointed as Exclusive Biomiq Skincare China Distributor. Source: OPAL update | Biomiq Distributor HD View: Turnaround from previous managementlooks on track. We are hosting XEN for a webinar on 11th June Register here ReadyTech (ASX:RDY) Unsolicited Non-Binding Indicative Proposal toβ¦